Lakshmi Nayak, Dana Farber Institute, talks about applying precision and immune-based treatments to patients with relapsed/refractory central nervous system (R/R CNS) lymphoma. Dr. Nayak discusses the significant advances in the treatment of R/R CNS lymphoma, however, explains that relapses and reoccurrences continue in about 50% of patients. Additionally, Dr. Nayak explains that about one-third of patients are refractory to the primary initial therapy, for this reason, there is an unmet need for primary R/R CNS lymphoma.
The European Lymphoma Institute is comprised of a network of top European specialists in the field of lymphoma who are dedicated to research, training and education. Together they look to define strategies to analyse and characterize lymphoma and its common diagnostic procedures and therapeutic standards, as well as to facilitate clinical and fundamental research. This all results in the advancement of lymphoma research and it guarantees equal access for all patients to the best possible care.